Blood Disorder Treatments

Published by: BCC Research

Published: Nov. 30, 2007 - 136 Pages

Table of Contents

INTRODUCTION

STUDY GOALS AND OBJECTIVES

SCOPE OF STUDY

METHODOLOGY AND INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED BCC REPORTS

BCC ONLINE SERVICES

DISCLAIMER

EXECUTIVE SUMMARY

EXECUTIVE SUMMARY

SUMMARY TABLE MARKET SIZE OF WORLDWIDE BLOOD

DISORDER TREATMENTS BY REVENUE AT MANUFACTURERS’

SALES LEVELS, THROUGH 2012 ($ MILLIONS)

SUMMARY FIGURE MARKET SIZE OF BLOOD DISORDER

TREATMENTS BY REVENUE AT MANUFACTURERS’ SALES

LEVELS, 2005-2012 ($ MILLIONS)

INDUSTRY OVERVIEW

STRUCTURE AND FUNCTION OF THE HEMATOLOGICAL

SYSTEM

BONE MARROW

BLOOD CELLS

Red Blood Cells

White Blood Cells

Platelets

SPLEEN

LYMPH SYSTEM

LIVER

NORMAL CLOTTING MECHANISMS

EFFECTS OF AGING ON THE HEMATOLOGIC SYSTEM

BLOOD-RELATED MEDICAL CONDITIONS

ANEMIA

TABLE 1 COMMON CAUSES OF ANEMIA

Anemia (Continued)

Anemia Caused by Decreased Erythrocyte Production

Iron Deficiency Anemia

Thalassemia

Megaloblastic Anemia

Vitamin B12 Deficiency

Anemia of Chronic Disease

Anemia Caused by Blood Loss

Anemia Caused by Increased Erythrocyte Destruction

Sickle Cell Disease

Glucose-6-Phosphate Dehydrogenase Deficiency

Acquired Hemolytic Anemia

Polycythemia

TABLE 2 TYPES OF ANEMIA

TABLE 2 (CONTINUED)

HEMOPHILIA

TABLE 3 COMMON CAUSES OF HEMOPHILIA

NEUTROPENIA

TABLE 4 COMMON INFECTIOUS CAUSES OF NEUTROPENIA

TABLE 5 COMMON MEDICATION CAUSES OF ANEMIA

THROMBOCYTOPENIA

TABLE 6 COMMON CAUSES OF THROMBOCYTOPENIA

THROMBOSIS

Thromboembolus

Deep Vein Thrombosis

TABLE 7 COMMON CAUSES OF THROMBOSIS

DEMOGRAPHICS AND STATISTICS

TABLE 8 U.S. CASES OF SELECTED CHRONIC CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007

TABLE 8 (CONTINUED)

FIGURE 1 U.S. CASES OF SELECTED LEADING CHRONIC CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007 (%)

TABLE 9 WORLDWIDE CASES OF SELECTED CHRONIC CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007

FIGURE 2 WORLDWIDE CASES OF SELECTED LEADING CHRONIC CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007 (%)

TABLE 10 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, THROUGH 2012 (MILLIONS)

FIGURE 3 U.S. POPULATION BY SELECTED AGE GROUPS, 2005-2012 (MILLIONS)

TABLE 11 WORLDWIDE POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, THROUGH 2012 (MILLIONS)

FIGURE 4 WORLDWIDE POPULATION BY SELECTED AGE GROUPS, 2005-2012 (MILLIONS)

LICENSING DISPUTES

Licensing Disputes (Continued)

Licensing Disputes (Continued)

Licensing Disputes (Continued)

REBATE ISSUES

FDA RESTRICTIONS ON ANEMIA DRUGS

TELEMEDICINE FOR HEMOPHILIA

HEMOPHILIA AND JOINT DAMAGE

EDUCATION

COST

PHARMACEUTICAL LANDSCAPE CHANGES

THE IMPACT OF BIOTECHNOLOGY

The Impact of Biotechnology (Continued)

The Impact of Biotechnology (Continued)

TABLE 12 MARKETED BIOTECHNOLOGY BLOOD TREATMENTS

TABLE 12 (CONTINUED)

TABLE 13 MARKETED BIOTECHNOLOGY PRODUCT IMPACT

TABLE 13 (CONTINUED)

BIOGENERIC IMPACT

SEDENTARY LIFESTYLES AND DVT

MEDICARE AND THE ELDERLY

Medicare and the Elderly (Continued)

AIRLINE TRAVEL ISSUES

Airline Travel Issues (Continued)

PHARMACEUTICAL REBATE ISSUES

PRODUCT SEGMENTS BY TYPE

ANEMIA TREATMENTS

Aranesp/Nespo (Darbepoetin Alfa)

Procrit/Eprex (Epoetin Alfa)

Epogen (Epoetin Alfa)

NeoRecormon/Epogin (Epoetin Beta)

TABLE 14 KEY ANEMIA TREATMENTS

Anabolic Steroids

Cyanocobalamin and Combinations

Erythropoiesis Stimulants

Folic Acid and Derivatives

Iron and Derivatives

HEMOPHILIA TREATMENTS

Recombinants Group (Baxter)

Kogenate

NovoSeven

TABLE 15 KEY HEMOPHILIA TREATMENTS

Antihemophilic Factor

Anti-Inhibitor Coagulant Complex

Factor IX Complex

NEUTROPENIA TREATMENTS

Neulasta/Neupopeg (Pegfilgrastim)

Neupogen/Granulokine (Filgrastim)

TABLE 16 KEY NEUTROPENIA TREATMENTS

Granulocyte Colony Stimulating Factor

Granulocyte Macrophage Colony Stimulating Factor

THROMBOSIS TREATMENTS

Lovenox (Enoxaparin Sodium)

Plavix (Clopidogrel Bisulfate)

TABLE 17 KEY THROMBOSIS TREATMENTS

Anticoagulants

Antiplatelet Agents

Antithrombin III Agents

Thrombin Inhibitors

Thrombolytic Agents

NEW APPROVALS

TABLE 18 NEWLY APPROVED BLOOD DISORDER TREATMENTS

TABLE 18 (CONTINUED)

FIGURE 5 PERCENT OF RECENT BLOOD DISORDER APPROVALS BY TREATMENT TYPE (%)

MARKET SIZE AND GROWTH

TABLE 19 GLOBAL MARKET FOR BLOOD DISORDER TREATMENTS, THROUGH 2012 ($ MILLIONS)

FIGURE 6 GLOBAL MARKET FOR BLOOD DISORDER TREATMENTS, 2005-2012 ($ MILLIONS)

BLOOD DISORDER TREATMENT MARKET BY GEOGRAPHY

TABLE 20 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE BLOOD DISORDER TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)

FIGURE 7 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE BLOOD DISORDER TREATMENTS MARKET, 2005-2012 ($ MILLIONS)

BLOOD DISORDER TREATMENT MARKETS BY SEGMENT

ANEMIA TREATMENTS MARKET

TABLE 21 GLOBAL MARKET FOR ANEMIA TREATMENTS, THROUGH 2012 ($ MILLIONS)

FIGURE 8 GLOBAL MARKET FOR ANEMIA TREATMENTS, 2005-2012 ($ MILLIONS)

TABLE 22 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE ANEMIA TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)

FIGURE 9 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE ANEMIA TREATMENTS MARKET, 2005-2012 ($ MILLIONS)

HEMOPHILIA TREATMENTS MARKET

TABLE 23 GLOBAL MARKET FOR HEMOPHILIA TREATMENTS, THROUGH 2012 ($ MILLIONS)

FIGURE 10 GLOBAL MARKET FOR HEMOPHILIA TREATMENTS, 2005-2012 ($ MILLIONS)

TABLE 24 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE HEMOPHILIA TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)

FIGURE 11 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE HEMOPHILIA TREATMENTS MARKET, 2005-2012 ($ MILLIONS)

NEUTROPENIA TREATMENTS MARKET

TABLE 25 GLOBAL MARKET FOR NEUTROPENIA TREATMENTS, THROUGH 2012 ($ MILLIONS)

FIGURE 12 GLOBAL MARKET FOR NEUTROPENIA TREATMENTS, 2005-2012 ($ MILLIONS)

TABLE 26 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE NEUTROPENIA TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)

FIGURE 13 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE NEUTROPENIA TREATMENTS MARKET, 2005-2012 ($ MILLIONS)

THROMBOSIS TREATMENTS

TABLE 27 GLOBAL MARKET FOR THROMBOSIS TREATMENTS, THROUGH 2012 ($ MILLIONS)

FIGURE 14 GLOBAL MARKET FOR THROMBOSIS TREATMENTS, 2005-2012 ($ MILLIONS)

TABLE 28 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE THROMBOSIS TREATMENTS MARKET, THROUGH 2012 ($ MILLIONS)

FIGURE 15 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE THROMBOSIS TREATMENTS MARKET, 2005-2012 ($ MILLIONS)

RESEARCH AND DEVELOPMENT

TABLE 29 SELECTED BLOOD DISORDER TREATMENTS IN DEVELOPMENT

TABLE 29 (CONTINUED)

TABLE 29 (CONTINUED)

TABLE 29 (CONTINUED)

TABLE 29 (CONTINUED)

TABLE 29 (CONTINUED)

TABLE 29 (CONTINUED)

TREATMENTS AWAITING APPROVAL/PHASE TRIALS

AWAITING APPROVAL

Angiomax/Angiox

Hemopure

Mircera/C.E.R.A./R744

EPOCH

Ferinject

Lovenox

Plavix

Soluble Ferric Pyrophosphate (SFP)

PHASE III CLINICAL TRIALS

AMG-531

Apixaban

ATryn

AZD-6140

Beriplex P/N

Idraparinux Long-Acting Pentasaccharide

Cangrelor

Elaprin

Ferumoxytol

Hematide

Hemospan

Hemoxin/Nicosan/Niprisan

ICA-17043

Mozobil (AMD3100)

NovoSeven

Oxygent

PolyHeme

Procrit (Epoetin Alfa)

Promacta (Eltrombopag Olamine)

Refacto AF

Rendix (Dabigatran Etexilate)

Rivaroxaban (BAY 59-7939)

INDUSTRY STRUCTURE

COMPETITIVE ANALYSIS

TABLE 30 TOTAL MANUFACTURERS’ MARKET SHARES OF BLOOD DISORDER TREATMENTS, 2007

TABLE 30 (CONTINUED)

FIGURE 17 TOTAL MANUFACTURERS’ MARKET SHARES OF BLOOD DISORDER TREATMENTS, 2007

ANEMIA TREATMENTS

TABLE 31 TOTAL MANUFACTURERS’ MARKET SHARES OF ANEMIA TREATMENTS, 2007

FIGURE 18 TOTAL MANUFACTURERS’ MARKET SHARES OF ANEMIA TREATMENTS, 2007 (%)

HEMOPHILIA TREATMENTS

TABLE 32 TOTAL MANUFACTURERS’ MARKET SHARES OF HEMOPHILIA TREATMENTS, 2007

FIGURE 19 TOTAL MANUFACTURERS’ MARKET SHARES OF HEMOPHILIA TREATMENTS, 2007 (%)

NEUTROPENIA TREATMENTS

TABLE 33 TOTAL MANUFACTURERS’ MARKET SHARES OF NEUTROPENIA TREATMENTS, 2007

FIGURE 20 TOTAL MANUFACTURERS’ MARKET SHARES OF NEUTROPENIA TREATMENTS, 2007 (%)

THROMBOSIS TREATMENTS

TABLE 34 TOTAL MANUFACTURERS’ MARKET SHARES OF THROMBOSIS TREATMENTS, 2007

FIGURE 21 TOTAL MANUFACTURERS’ MARKET SHARES OF THROMBOSIS TREATMENTS, 2007

INDUSTRY PARTICIPANTS BY PRODUCT TYPE

TABLE 35 BLOOD DISORDER TREATMENT MANUFACTURERS BY PRODUCT TYPE, 2007

FIGURE 22 BLOOD DISORDER TREATMENT MARKETS—NUMBER OF KEY MANUFACTURERS BY PRODUCT TYPE, 2007 (%)

PATENTS

PATENT ANALYSIS BY MANUFACTURER

TABLE 36 SELECTED MANUFACTURER PATENTS FOR BLOOD DISORDER AND RELATED TECHNOLOGY BY APPLICATION, 1976-PRESENT

PATENTS BY APPLICATION

Anemia Applications

Hemophilia

Neutropenia

Thrombosis

LEADING MARKET MANUFACTURERS

TABLE 37 PATENT ANALYSIS BY SELECTED LEADING BLOOD DISORDER TREATMENT MANUFACTURERS, 1976-PRESENT

COMPANY PROFILES

AMGEN, INC.

BAXTER INTL., INC.

BAYER AG

BIOPURE CORPORATION

BRISTOL-MYERS SQUIBB CO

CHUGAI PHARMACEUTICAL CO., LTD.

CSL BEHRING

GENZYME

TEL: 617/252-7500

GLAXOSMITHKLINE, PLC

ICAGEN, INC

MEDICINES COMPANY (THE)

NOVO NORDISK A/S

ORTHO BIOTECH PRODUCTS, LP

ROCHE

SANOFI-AVENTIS

SCHERING-PLOUGH CORP

WYETH

APPENDICES

COMPANY CONTACT INFORMATION

TABLE 38 LIST OF COMPANIES

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

TABLE 38 (CONTINUED)

BLOOD DISORDER ASSOCIATIONS AND RESOURCES CONTACT INFORMATION

BLOOD DISORDER ASSOCIATIONS (CONTINUED)

BLOOD DISORDER ASSOCIATIONS (CONTINUED)

LIST OF TABLES

SUMMARY TABLE MARKET SIZE OF WORLDWIDE BLOOD DISORDER

TREATMENTS BY REVENUE AT MANUFACTURERS’ SALES

LEVELS, THROUGH 2012 ($ MILLIONS)

TABLE 1 COMMON CAUSES OF ANEMIA

TABLE 2 TYPES OF ANEMIA

TABLE 3 COMMON CAUSES OF HEMOPHILIA

TABLE 4 COMMON INFECTIOUS CAUSES OF NEUTROPENIA

TABLE 5 COMMON MEDICATION CAUSES OF ANEMIA

TABLE 6 COMMON CAUSES OF THROMBOCYTOPENIA

TABLE 7 COMMON CAUSES OF THROMBOSIS

TABLE 8 U.S. CASES OF SELECTED CHRONIC CONDITIONS/

DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED

2007

TABLE 9 WORLDWIDE CASES OF SELECTED CHRONIC

CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS,

ESTIMATED 2007

TABLE 10 U.S. POPULATION BY SELECTED AGE GROUPS AND BY

PERCENT OF TOTAL POPULATION, THROUGH 2012 (MILLIONS)

TABLE 11 WORLDWIDE POPULATION BY SELECTED AGE GROUPS

AND BY PERCENT OF TOTAL POPULATION, THROUGH 2012

(MILLIONS)

TABLE 12 MARKETED BIOTECHNOLOGY BLOOD TREATMENTS

TABLE 13 MARKETED BIOTECHNOLOGY PRODUCT IMPACT

TABLE 14 KEY ANEMIA TREATMENTS

TABLE 15 KEY HEMOPHILIA TREATMENTS

TABLE 16 KEY NEUTROPENIA TREATMENTS

TABLE 17 KEY THROMBOSIS TREATMENTS

TABLE 18 NEWLY APPROVED BLOOD DISORDER TREATMENTS

TABLE 19 GLOBAL MARKET FOR BLOOD DISORDER

TREATMENTS, THROUGH 2012 ($ MILLIONS)

TABLE 20 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE

WORLDWIDE BLOOD DISORDER TREATMENTS MARKET,

THROUGH 2012 ($ MILLIONS)

TABLE 21 GLOBAL MARKET FOR ANEMIA TREATMENTS, THROUGH

2012 ($ MILLIONS)

TABLE 22 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE

WORLDWIDE ANEMIA TREATMENTS MARKET, THROUGH 2012

($ MILLIONS)

TABLE 23 GLOBAL MARKET FOR HEMOPHILIA TREATMENTS,

THROUGH 2012 ($ MILLIONS)

TABLE 24 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE

WORLDWIDE HEMOPHILIA TREATMENTS MARKET, THROUGH

2012 ($ MILLIONS)

TABLE 25 GLOBAL MARKET FOR NEUTROPENIA TREATMENTS,

THROUGH 2012 ($ MILLIONS)

TABLE 26 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE

WORLDWIDE NEUTROPENIA TREATMENTS MARKET, THROUGH

2012 ($ MILLIONS)

TABLE 27 GLOBAL MARKET FOR THROMBOSIS TREATMENTS,

THROUGH 2012 ($ MILLIONS)

TABLE 28 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE

WORLDWIDE THROMBOSIS TREATMENTS MARKET, THROUGH

2012 ($ MILLIONS)

TABLE 29 SELECTED BLOOD DISORDER TREATMENTS IN

DEVELOPMENT

TABLE 30 TOTAL MANUFACTURERS’ MARKET SHARES OF BLOOD

DISORDER TREATMENTS, 2007

TABLE 31 TOTAL MANUFACTURERS’ MARKET SHARES OF ANEMIA

TREATMENTS, 2007

TABLE 32 TOTAL MANUFACTURERS’ MARKET SHARES OF

HEMOPHILIA TREATMENTS, 2007

TABLE 33 TOTAL MANUFACTURERS’ MARKET SHARES OF

NEUTROPENIA TREATMENTS, 2007

TABLE 34 TOTAL MANUFACTURERS’ MARKET SHARES OF

THROMBOSIS TREATMENTS, 2007

TABLE 35 BLOOD DISORDER TREATMENT MANUFACTURERS BY

PRODUCT TYPE, 2007

TABLE 36 SELECTED MANUFACTURER PATENTS FOR BLOOD

DISORDER AND RELATED TECHNOLOGY BY APPLICATION, 1976-

PRESENT

TABLE 37 PATENT ANALYSIS BY SELECTED LEADING BLOOD

DISORDER TREATMENT MANUFACTURERS, 1976-PRESENT

TABLE 38 LIST OF COMPANIES

LIST OF FIGURES

SUMMARY FIGURE MARKET SIZE OF BLOOD DISORDER

TREATMENTS BY REVENUE AT MANUFACTURERS’ SALES

LEVELS, 2005-2012 ($ MILLIONS)

FIGURE 1 U.S. CASES OF SELECTED LEADING CHRONIC

CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS,

ESTIMATED 2007 (%)

FIGURE 2 WORLDWIDE CASES OF SELECTED LEADING CHRONIC

CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS,

ESTIMATED 2007 (%)

FIGURE 3 U.S. POPULATION BY SELECTED AGE GROUPS, 2005-2012

(MILLIONS)

FIGURE 4 WORLDWIDE POPULATION BY SELECTED AGE GROUPS,

2005-2012 (MILLIONS)

FIGURE 5 PERCENT OF RECENT BLOOD DISORDER APPROVALS BY

TREATMENT TYPE (%)

FIGURE 6 GLOBAL MARKET FOR BLOOD DISORDER TREATMENTS,

2005-2012 ($ MILLIONS)

FIGURE 7 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE

WORLDWIDE BLOOD DISORDER TREATMENTS MARKET, 2005-2012

($ MILLIONS)

FIGURE 8 GLOBAL MARKET FOR ANEMIA TREATMENTS, 2005-2012

($ MILLIONS)

FIGURE 9 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE

WORLDWIDE ANEMIA TREATMENTS MARKET, 2005-2012

($ MILLIONS)

FIGURE 10 GLOBAL MARKET FOR HEMOPHILIA TREATMENTS, 2005-

2012 ($ MILLIONS)

FIGURE 11 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE

WORLDWIDE HEMOPHILIA TREATMENTS MARKET, 2005-2012

($ MILLIONS)

FIGURE 12 GLOBAL MARKET FOR NEUTROPENIA TREATMENTS,

2005-2012 ($ MILLIONS)

FIGURE 13 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE

WORLDWIDE NEUTROPENIA TREATMENTS MARKET, 2005-2012

($ MILLIONS)

FIGURE 14 GLOBAL MARKET FOR THROMBOSIS TREATMENTS,

2005-2012 ($ MILLIONS)

FIGURE 15 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE

WORLDWIDE THROMBOSIS TREATMENTS MARKET, 2005-2012

($ MILLIONS)

FIGURE 16 NUMBER OF BLOOD DISORDER TREATMENTS IN

DEVELOPMENT BY PHASE (%)

FIGURE 17 TOTAL MANUFACTURERS’ MARKET SHARES OF BLOOD

DISORDER TREATMENTS, 2007

FIGURE 18 TOTAL MANUFACTURERS’ MARKET SHARES OF ANEMIA

TREATMENTS, 2007 (%)

FIGURE 19 TOTAL MANUFACTURERS’ MARKET SHARES OF

HEMOPHILIA TREATMENTS, 2007 (%)

FIGURE 20 TOTAL MANUFACTURERS’ MARKET SHARES OF

NEUTROPENIA TREATMENTS, 2007 (%)

FIGURE 21 TOTAL MANUFACTURERS’ MARKET SHARES OF

THROMBOSIS TREATMENTS, 2007

FIGURE 22 BLOOD DISORDER TREATMENT MARKETS—NUMBER OF

KEY MANUFACTURERS BY PRODUCT TYPE, 2007 (%)

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.